Safety update of etanercept treatment for moderate to severe plaque psoriasis.

Safety update of etanercept treatment for moderate to severe plaque psoriasis. Expert Opin Drug Saf. 2020 Mar 17;: Authors: Campanati A, Diotallevi F, Martina E, Paolinelli M, Radi G, Offidani A Abstract Introduction: Conventional topical therapies and disease-modifying anti-rheumatic drugs (DMARDs) for patients with psoriasis are often linked to inadequate outcomes and risk of multiple adverse effects. Biologic agents such as etanercept (ETN) have revolutionized the therapeutic management of psoriasis, allowing the treatment of most difficult cases, and fragile patients.Areas covered: The authors searched PubMed using the term "psoriasis", "etanercept" and "safety". Articles considered by the authors to be most relevant, such as randomized controlled studies, cohort studies, and review articles placing emphasis on studies of efficacy and safety, were selected. Case reports and letters relating to safety were also included. The main sources of data referenced by these articles were also included in the review. Besides, to get the relevant studies, the reference lists were examined to identify the potentially available studies. The aim of this review is to describe the safety profile of ETN, used for psoriasis treatment, focusing on related clinical implications.Expert opinion: ETN has a favourable safety profile, and its use should be largely considered in psoriatic patients. Caution should be recommended in case of chronic heart fai...
Source: Expert Opinion on Drug Safety - Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research